On 29 June 2026, Health Canada approved Apotex’s Sevmia™, generic equivalent of Novo Nordisk’s Wegovy® (semaglutide). Sevmia™ is the first generic semaglutide product approved in Canada for chronic weight management.
Sevmia™ was developed in partnership with Orbicular Pharmaceutical Technologies and is approved as a solution for subcutaneous injection in a pre-filled pen (4 mg/pen; 1.34 mg/mL). It is indicated for once-weekly treatment of patients aged 12 years and over, as a supplement to a reduced calorie diet and increased physical acitivity for chronic weight management.
Generic semaglutide products have previously been approved in Canada only for the treatment of type 2 diabetes. Apotex’s Apo-Semaglutide Injection™ was approved on 1 May 2026 and launched 14 May 2026, while Dr Reddy’s Laboratories’ generic semaglutide injection was approved on 29 April 2026 and also launched in Canada on 14 May 2026.
Health Canada is reviewing numerous submissions for generic semaglutide, including applications by AA Pharma, Aspen Pharmacare, Teva, Taro Pharmaceuticals, Zydus Lifesciences and Sandoz (which is planning a 2026 generic semaglutide launch in Canada). Further generic semaglutide approvals and launches are therefore expected in Canada in the coming months.